Keywords: palatin, az, extend, melanocortin, receptor, alliance, usa

Palatin and AZ extend melanocortin receptor R&D alliance

Article | 15 December 2008

Print This

The USA's Palatin Technologies has extended its R&D collaboration and license agreement with Anglo-Swedish drug major AstraZeneca focused on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in